Last week, the European Commission expanded its order for Moderna's Omicron-targeted vaccine by ... the disease and save lives," said MHRA CEO Dr June Raine. "What this bivalent vaccine gives ...

That could mean it is less susceptible to the loss of efficacy to vaccines that can occur when there are changes in the spoke protein – as witnessed with the new Omicron variant. The results of ...

A social media post claims that Moderna’s CEO confessed to creating a COVID vaccine before the pandemic. After fact checking, we found that the claim is false. According to an Instagram post ...

Moderna stock reversed losses on its fourth-quarter report after CEO Stephane Bancel deflected concerns over RFK Jr. Is MRNA stock a buy?

After tough year, Moderna CEO confronts challenges for RSV, COVID businesses in shareholder letter Moderna developed its own generative AI application called mChat and rolled it out company-wide.

After tough year, Moderna CEO confronts challenges for RSV, COVID businesses in shareholder letter Inventory write-downs and manufacturing charges are nothing new for Moderna, which has struggled ...

The Claim: According to an Instagram post, “Moderna CEO confessed to creating the COVID-19 vaccine 2 years before the virus was released to the world. This means that they knew COVID was coming ...

Moderna (MRNA) stock surged 7% this week following Oracle (ORCL) CEO Larry Ellison’s claims that artificial intelligence (AI) could help develop messenger RNA-based (mRNA) vaccines to cure cancer.

Chief Executive Stephane Bancel says Moderna will work with the Trump administration. Moderna stock rose in midday trades.

It expects to end 2025 with a cash balance of $6 billion. Moderna CEO Stephane Bancel commented, "In 2024, we achieved $3.0 - 3.1 billion in product sales, approval of our RSV vaccine and ...

The Company expects to start a registrational study in 2025. Published Moderna CEO Stéphane Bancel's annual letter to shareholders on January 6, 2025. Provided business and pipeline updates at ...

The U.S. government has handed Moderna almost $600 million to accelerate its work on various bird flu vaccines as well as work on mRNA vaccines for other influenza strains with pandemic potential.